🇺🇸 Ciclophosphamide in United States

15 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Graft Versus Host Disease In Liver — 2 reports (13.33%)
  2. Cholestasis — 2 reports (13.33%)
  3. Hepatitis — 2 reports (13.33%)
  4. Hepatitis C Virus Test Positive — 2 reports (13.33%)
  5. Hepatocellular Injury — 2 reports (13.33%)
  6. Abdominal Pain Upper — 1 report (6.67%)
  7. Condition Aggravated — 1 report (6.67%)
  8. Diffuse Large B-Cell Lymphoma — 1 report (6.67%)
  9. Drug Ineffective — 1 report (6.67%)
  10. Escherichia Sepsis — 1 report (6.67%)

Source database →

Ciclophosphamide in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Ciclophosphamide approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Ciclophosphamide in United States?

PETHEMA Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.